Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study.

Sood A, Petersen H, Qualls C, Meek PM, Vazquez-Guillamet R, Celli BR, Tesfaigzi Y.

Respir Res. 2016 Nov 10;17(1):147.

2.

Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers.

Diaz AA, Petersen H, Meek P, Sood A, Celli B, Tesfaigzi Y.

Chest. 2016 Oct;150(4):869-876. doi: 10.1016/j.chest.2016.06.011.

PMID:
27321735
3.

A retrospective analysis to identify predictors of COPD-related rehospitalization.

Roberts MH, Clerisme-Beaty E, Kozma CM, Paris A, Slaton T, Mapel DW.

BMC Pulm Med. 2016 Apr 30;16(1):68. doi: 10.1186/s12890-016-0231-3.

4.

Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity.

Mapel DW, Dalal AA, Johnson PT, Becker LK, Hunter AG.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 30;10:1477-86. doi: 10.2147/COPD.S78827.

5.

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease.

Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, Meek P, Owen CA, Petersen H, Pinto-Plata V, Schnohr P, Sood A, Soriano JB, Tesfaigzi Y, Vestbo J.

N Engl J Med. 2015 Jul 9;373(2):111-22. doi: 10.1056/NEJMoa1411532.

6.

The impact of chronic pain on direct medical utilization and costs in chronic obstructive pulmonary disease.

Roberts MH, Mapel DW, Thomson HN.

Clinicoecon Outcomes Res. 2015 Mar 26;7:173-84. doi: 10.2147/CEOR.S80424.

7.

Chronic Bronchitis Is Associated With Worse Symptoms and Quality of Life Than Chronic Airflow Obstruction.

Meek PM, Petersen H, Washko GR, Diaz AA, Kim V, Sood A, Tesfaigzi Y.

Chest. 2015 Aug;148(2):408-16. doi: 10.1378/chest.14-2240.

8.

A genome-wide association study of chronic obstructive pulmonary disease in Hispanics.

Chen W, Brehm JM, Manichaikul A, Cho MH, Boutaoui N, Yan Q, Burkart KM, Enright PL, Rotter JI, Petersen H, Leng S, Obeidat M, Bossé Y, Brandsma CA, Hao K, Rich SS, Powell R, Avila L, Soto-Quiros M, Silverman EK, Tesfaigzi Y, Barr RG, Celedón JC.

Ann Am Thorac Soc. 2015 Mar;12(3):340-8. doi: 10.1513/AnnalsATS.201408-380OC.

9.

Epigenetic change (GATA-4 gene methylation) is associated with health status in chronic obstructive pulmonary disease.

Meek PM, Sood A, Petersen H, Belinsky SA, Tesfaigzi Y.

Biol Res Nurs. 2015 Mar;17(2):191-8. doi: 10.1177/1099800414538113.

PMID:
24973415
10.

Probabilistic data linkage: a case study of comparative effectiveness in COPD.

Blanchette CM, Dekoven M, De AP, Roberts M.

Drugs Context. 2013 Oct 31;2013:212258. doi: 10.7573/dic.212258.

11.

Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion.

Bruse S, Petersen H, Weissfeld J, Picchi M, Willink R, Do K, Siegfried J, Belinsky SA, Tesfaigzi Y.

Respir Res. 2014 Jan 9;15:2. doi: 10.1186/1465-9921-15-2.

12.

Spirometry and health status worsen with weight gain in obese smokers but improve in normal-weight smokers.

Sood A, Petersen H, Meek P, Tesfaigzi Y.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):274-81. doi: 10.1164/rccm.201306-1060OC.

13.

Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use.

Petersen H, Sood A, Meek PM, Shen X, Cheng Y, Belinsky SA, Owen CA, Washko G, Pinto-Plata V, Kelly E, Celli B, Tesfaigzi Y.

Chest. 2014 Apr;145(4):695-703. doi: 10.1378/chest.13-0799.

14.
15.

Methylated Genes in Sputum Among Older Smokers With Asthma.

Sood A, Petersen H, Blanchette CM, Meek P, Picchi MA, Belinsky SA, Tesfaigzi Y.

Chest. 2012 Aug;142(2):425-31.

16.

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims.

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT.

Int J Chron Obstruct Pulmon Dis. 2011;6:573-81. doi: 10.2147/COPD.S16975.

17.

Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management.

Roberts M, Mapel D, Petersen H, Blanchette C, Ramachandran S.

J Med Econ. 2011;14(6):769-76. doi: 10.3111/13696998.2011.622817.

PMID:
21942463
18.

New Mexican Hispanic smokers have lower odds of chronic obstructive pulmonary disease and less decline in lung function than non-Hispanic whites.

Bruse S, Sood A, Petersen H, Liu Y, Leng S, Celedón JC, Gilliland F, Celli B, Belinsky SA, Tesfaigzi Y.

Am J Respir Crit Care Med. 2011 Dec 1;184(11):1254-60. doi: 10.1164/rccm.201103-0568OC.

19.

Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data.

Mapel DW, Dutro MP, Marton JP, Woodruff K, Make B.

BMC Health Serv Res. 2011 Feb 23;11:43. doi: 10.1186/1472-6963-11-43.

20.

A new method for examining the cost savings of reducing COPD exacerbations.

Mapel DW, Schum M, Lydick E, Marton JP.

Pharmacoeconomics. 2010;28(9):733-49. doi: 10.2165/11535600-000000000-00000.

PMID:
20799755
Items per page

Supplemental Content

Loading ...
Support Center